Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications: review article
Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. La...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 16, 2023
|
| In: |
EXCLI journal
Year: 2023, Jahrgang: 22, Pages: 146-168 |
| ISSN: | 1611-2156 |
| DOI: | 10.17179/excli2022-5653 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.17179/excli2022-5653 Verlag, kostenfrei, Volltext: https://www.excli.de/index.php/excli/article/view/5653 
|
| Verfasserangaben: | Mohammad Alwahsh, Joviana Farhat, Shahd Talhouni, Lama Hamadneh, Roland Hergenröder |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1890461571 | ||
| 003 | DE-627 | ||
| 005 | 20240703183114.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240603s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.17179/excli2022-5653 |2 doi | |
| 035 | |a (DE-627)1890461571 | ||
| 035 | |a (DE-599)KXP1890461571 | ||
| 035 | |a (OCoLC)1443679350 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a AlWahsh, Mohammad |d 1994- |e VerfasserIn |0 (DE-588)1197736433 |0 (DE-627)1679469517 |4 aut | |
| 245 | 1 | 0 | |a Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications |b review article |c Mohammad Alwahsh, Joviana Farhat, Shahd Talhouni, Lama Hamadneh, Roland Hergenröder |
| 264 | 1 | |c January 16, 2023 | |
| 300 | |a 23 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 03.06.2024 | ||
| 520 | |a Bortezomib (BTZ) is a first-in-class reversible and selective proteasome inhibitor. It inhibits the ubiquitin proteasome pathway that leads to the degradation of many intracellular proteins. Initially, BTZ was FDA approved for the treatment of refractory or relapsed multiple myeloma (MM) in 2003. Later, its usage was approved for patients with previously untreated MM. In 2006, BTZ was approved for the treatment of relapsed or refractory Mantle Cell Lymphoma (MCL) and, in 2014, for previously untreated MCL. BTZ has been extensively studied either alone or in combination with other drugs for the treatment of different liquid tumors especially in MM. However, limited data evaluated the efficacy and safety of using BTZ in patients with solid tumors. In this review, we will discuss the advanced and novel mechanisms of action of BTZ documented in MM, solid tumors and liquid tumors. Moreover, we will shed the light on the newly discovered pharmacological effects of BTZ in other prevalent diseases. | ||
| 650 | 4 | |a bortezomib | |
| 650 | 4 | |a liquid tumors | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a proteasome inhibitor | |
| 650 | 4 | |a solid tumors | |
| 700 | 1 | |a Farhat, Joviana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Talhouni, Shahd |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hamadneh, Lama |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hergenröder, Roland |e VerfasserIn |0 (DE-588)1148028897 |0 (DE-627)1007506040 |0 (DE-576)496155377 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t EXCLI journal |d Dortmund : IfADo - Leibniz Research Centre for Working Environment and Human Factors, 2002 |g 22(2023), Seite 146-168 |h Online-Ressource |w (DE-627)377753955 |w (DE-600)2132560-1 |w (DE-576)27824162X |x 1611-2156 |7 nnas |a Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications review article |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g pages:146-168 |g extent:23 |a Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications review article |
| 856 | 4 | 0 | |u https://doi.org/10.17179/excli2022-5653 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.excli.de/index.php/excli/article/view/5653 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240603 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 1197736433 |a AlWahsh, Mohammad |m 1197736433:AlWahsh, Mohammad |d 60000 |e 60000PA1197736433 |k 0/60000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1890461571 |e 4533654967 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 03.06.2024"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1890461571","language":["eng"],"title":[{"subtitle":"review article","title":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications","title_sort":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications"}],"person":[{"family":"AlWahsh","given":"Mohammad","display":"AlWahsh, Mohammad","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Farhat","given":"Joviana","roleDisplay":"VerfasserIn","display":"Farhat, Joviana","role":"aut"},{"display":"Talhouni, Shahd","roleDisplay":"VerfasserIn","role":"aut","family":"Talhouni","given":"Shahd"},{"given":"Lama","family":"Hamadneh","role":"aut","roleDisplay":"VerfasserIn","display":"Hamadneh, Lama"},{"family":"Hergenröder","given":"Roland","roleDisplay":"VerfasserIn","display":"Hergenröder, Roland","role":"aut"}],"physDesc":[{"extent":"23 S."}],"relHost":[{"id":{"issn":["1611-2156"],"eki":["377753955"],"zdb":["2132560-1"]},"origin":[{"publisherPlace":"Dortmund ; Dortmund ; Mainz","dateIssuedDisp":"18. December 2002-","publisher":"IfADo - Leibniz Research Centre for Working Environment and Human Factors ; Technische Universität Dortmund ; Universität"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"EXCLI journal","subtitle":"experimental and clinical sciences","title_sort":"EXCLI journal"}],"part":{"volume":"22","text":"22(2023), Seite 146-168","extent":"23","year":"2023","pages":"146-168"},"titleAlt":[{"title":"international online journal for advances in science"}],"pubHistory":["Volume 1 (2002)-"],"recId":"377753955","language":["eng"],"disp":"Bortezomib advanced mechanisms of action in multiple myeloma, solid and liquid tumors along with its novel therapeutic applications review articleEXCLI journal","note":["Gesehen am 25. November 2021","ROAD, OA-J"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"origin":[{"dateIssuedDisp":"January 16, 2023","dateIssuedKey":"2023"}],"id":{"doi":["10.17179/excli2022-5653"],"eki":["1890461571"]},"name":{"displayForm":["Mohammad Alwahsh, Joviana Farhat, Shahd Talhouni, Lama Hamadneh, Roland Hergenröder"]}} | ||
| SRT | |a ALWAHSHMOHBORTEZOMIB1620 | ||